比如在弥漫大B细胞淋巴瘤 (DLBCL)中外周血清microRNA-21高表达，通过对患者血液中的microRNA-21检测，可以判断DLBCL恶性度，有利于淋巴瘤诊断危险分组及治疗方案选择.

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

本文作者之一北京大学分子医学研究所研究员刘颖曾在加里·鲁弗肯实验室从事博士后研究（希望再接再厉，争取拿诺奖）。本文另一作者中国科学技术大学生命科学学院教授光寿红从事秀丽线虫研究十几年，当中见过安博斯和鲁弗肯很多次，也多次得到他们的指点和帮助，一直心里 ...

10.7知识分子The Intellectual 导  读刚刚，瑞典卡罗琳医学院宣布，2024年诺贝尔生理医学颁给美国马萨诸塞州大学医学院教授维克托·安博斯（Victor Ambros）和哈佛大学医学院教授加里·鲁弗肯（Gary ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

In the late 1980s, Ambros and Ruvkun were postdoctoral researchers in the laboratory of Robert Horvitz, who received the ...

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer ...

MIT study reveals 5-fluorouracil functions by disrupting RNA, not DNA, potentially impacting cancer treatment.

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Nobel Prize for Physiology awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in ...

MicroRNAs, or miRNAs, are small, non-coding molecules of RNA. They play an important role in determining how much messenger RNA (mRNA), which carries genetic information, eventually gets translated ...